FDA Clears AI-Powered Fetal Ultrasound Analysis Software from DeepEcho
The AI software reportedly facilitates ease of use and improved accuracy in fetal ultrasound evaluations.
The Food and Drug Administration (FDA) has granted 510(k) clearance for an emerging artificial intelligence (AI)-enabled software to enhance fetal ultrasound assessment.
The DeepEcho AI software provides biometric measurement calculations through automated segmentation of anatomical landmarks, according to DeepEcho.
Emphasizing ease of use and accessibility for clinicians, DeepEcho said its recently FDA-cleared AI software enables one to collect the relevant fetal biometry images and planes with three short video loops. (Image courtesy of DeepEcho.)
Emphasizing ease of use and accessibility for clinicians, DeepEcho said the AI software enables one to collect the relevant fetal biometry images and planes with three short video loops. Through selection of the appropriate planes and suggested measurements, the AI software facilitates greater than 95 percent accuracy, according to DeepEcho.
"This milestone underscores the power of combining AI with clinical expertise to solve some of the most critical problems in healthcare," added Saad Slimani, M.D., M.S., co-founder and chief medical officer of DeepEcho. "With this FDA clearance, we are one step closer to making early, accurate prenatal diagnosis universally accessible and helping clinicians deliver better outcomes for families."
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Reducing the Interval Breast Cancer Rate of Screening DBT: Can AI Have an Impact?
August 4th 2025In a retrospective review of screening digital breast tomosynthesis (DBT) exams for over 200 women with interval breast cancers, researchers found that AI provided accurate localization of cancers in 32.6 percent of the cases.
